U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856291) titled 'Response to Semaglutide in Non-diabetic Obese Patients with Varying Degrees of Insulin Resistance' on Feb. 18.
Brief Summary: Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this var...